Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$14.17
-3.5%
$14.23
$10.57
$33.33
$2.13B1.331.14 million shs1.47 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$28.09
-2.5%
$27.76
$17.82
$30.69
$2.10B0.05555,431 shs404,501 shs
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
$8.07
-3.1%
$7.16
$4.70
$10.44
$629.36M2.451.32 million shs812,810 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$36.37
-3.8%
$33.47
$27.12
$60.90
$2.26B2.41967,155 shs757,747 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-3.54%-1.12%-2.61%+12.91%-39.26%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-2.47%+3.23%-0.74%+36.82%+29.99%
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-3.12%+8.03%+12.55%+47.80%+3.20%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-3.78%-1.65%+8.50%-5.41%-35.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
4.6077 of 5 stars
4.51.00.04.73.43.30.0
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.506 of 5 stars
3.54.00.00.02.93.30.6
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
2.1969 of 5 stars
3.61.00.00.03.30.80.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.186 of 5 stars
3.45.00.04.41.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
3.06
Buy$33.71137.93% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.00
Buy$39.3340.03% Upside
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
3.27
Buy$25.50215.99% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4038.58% Upside

Current Analyst Ratings Breakdown

Latest MNMD, TWST, DNLI, and KNSA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.00
5/19/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $27.00
5/13/2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/9/2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
5/8/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$30.00 ➝ $29.00
5/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00
5/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$80.00 ➝ $32.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/A$8.53 per shareN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$423.24M4.84N/AN/A$6.60 per share4.26
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
N/AN/AN/AN/A$3.21 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.96N/AN/A$8.07 per share4.51
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$422.77M-$2.67N/AN/AN/AN/A-35.90%-32.41%7/30/2025 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-$43.19M-$0.25N/A112.36N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%8/12/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/4/2025 (Confirmed)

Latest MNMD, TWST, DNLI, and KNSA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$0.37N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.73N/AN/AN/AN/AN/A
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
7/22/2025Q2 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.08N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
-$0.36-$0.35+$0.01-$0.35N/AN/A
5/6/2025Q1 2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.71-$0.78-$0.07-$0.78$3.24 millionN/A
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
4/29/2025Q1 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.02$0.11+$0.09$0.11$128.35 million$137.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/A
9.56
9.56
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.66
3.43
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
0.10
7.27
7.27
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24
CompanyEmployeesShares OutstandingFree FloatOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430145.28 million127.12 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22072.97 million33.95 millionOptionable
Mind Medicine (MindMed) Inc. stock logo
MNMD
Mind Medicine (MindMed)
4075.55 million73.85 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

Twist Bioscience: Still Not There Yet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$14.17 -0.52 (-3.54%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$14.14 -0.03 (-0.18%)
As of 08:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.09 -0.71 (-2.47%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$28.30 +0.21 (+0.75%)
As of 07/15/2025 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Mind Medicine (MindMed) stock logo

Mind Medicine (MindMed) NASDAQ:MNMD

$8.07 -0.26 (-3.12%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$8.26 +0.20 (+2.42%)
As of 08:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$36.37 -1.43 (-3.78%)
Closing price 07/15/2025 04:00 PM Eastern
Extended Trading
$35.92 -0.45 (-1.22%)
As of 08:16 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.